Development of pharmaceutical products is subject to regulation by the FDA and foreign regulatory authorities and requires approval before they may be clinically tested and commercially marketed for human therapeutic use. Through the knowledge gained from understanding the genetic cause of a disease PRx endeavors to identify, modify or combine existing commercially available FDA approved compounds for new uses. PRx will use NHP-07, its first therapeutic candidate for the treatment of endometriosis, as a model for the creation and discovery of new drug opportunities. As it is a long and costly process to get new drugs approved, PRx will endeavor to develop these new opportunities through strategic partnerships with large pharmaceutical companies.